Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Dec 15;98(12):2866–2873. doi: 10.1172/JCI119115

Functional analysis of the mutations in the human cardiac beta-myosin that are responsible for familial hypertrophic cardiomyopathy. Implication for the clinical outcome.

M Sata 1, M Ikebe 1
PMCID: PMC507754  PMID: 8981935

Abstract

More than 30 missense mutations in the beta-cardiac myosin heavy chain gene have been shown to be responsible for familial hypertrophic cardiomyopathy. To clarify the effects of these point mutations on myosin motor function, we expressed wild-type and mutant human beta-cardiac myosin heavy chains in insect cells with human cardiac light chains. The wild-type myosin was well purified with similar enzymatic and motor activities to those of the naturally isolated V3 cardiac myosin. Arg249-->Gln and Arg453-->Cys mutations resulted in decreased actin translocating activity (61 and 23% of the wild-type, respectively) with decreased intrinsic ATPase activity. Arg403-->Gln mutation greatly decreased actin translocating activity (27% of wild type) with a 3.3-fold increased dissociation constant for actin, while intrinsic ATPase activity was unchanged. Val606-->Met mutation only mildly affected the actin translocating activity as well as ATPase activity of myosin. The degree of deterioration by each mutation was closely correlated with the prognosis of the affected kindreds, indicating that myosin dysfunction caused by the point mutations is responsible for the pathogenesis of the disease. Structure/function relationship of myosin is discussed.

Full Text

The Full Text of this article is available as a PDF (384.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anan R., Greve G., Thierfelder L., Watkins H., McKenna W. J., Solomon S., Vecchio C., Shono H., Nakao S., Tanaka H. Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest. 1994 Jan;93(1):280–285. doi: 10.1172/JCI116957. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  3. Clark C. E., Henry W. L., Epstein S. E. Familial prevalence and genetic transmission of idiopathic hypertrophic subaortic stenosis. N Engl J Med. 1973 Oct 4;289(14):709–714. doi: 10.1056/NEJM197310042891402. [DOI] [PubMed] [Google Scholar]
  4. Cuda G., Fananapazir L., Zhu W. S., Sellers J. R., Epstein N. D. Skeletal muscle expression and abnormal function of beta-myosin in hypertrophic cardiomyopathy. J Clin Invest. 1993 Jun;91(6):2861–2865. doi: 10.1172/JCI116530. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dalla Libera L., Hoffmann E., Floroff M., Jackowski G. Isolation and nucleotide sequence of the cDNA encoding human ventricular myosin light chain 2. Nucleic Acids Res. 1989 Mar 25;17(6):2360–2360. doi: 10.1093/nar/17.6.2360. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Eisenberg E., Hill T. L. Muscle contraction and free energy transduction in biological systems. Science. 1985 Mar 1;227(4690):999–1006. doi: 10.1126/science.3156404. [DOI] [PubMed] [Google Scholar]
  7. Epstein N. D., Cohn G. M., Cyran F., Fananapazir L. Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in the beta-myosin heavy chain gene. A 908Leu----Val mutation and a 403Arg----Gln mutation. Circulation. 1992 Aug;86(2):345–352. doi: 10.1161/01.cir.86.2.345. [DOI] [PubMed] [Google Scholar]
  8. Fananapazir L., Epstein N. D. Genotype-phenotype correlations in hypertrophic cardiomyopathy. Insights provided by comparisons of kindreds with distinct and identical beta-myosin heavy chain gene mutations. Circulation. 1994 Jan;89(1):22–32. doi: 10.1161/01.cir.89.1.22. [DOI] [PubMed] [Google Scholar]
  9. Fisher A. J., Smith C. A., Thoden J. B., Smith R., Sutoh K., Holden H. M., Rayment I. X-ray structures of the myosin motor domain of Dictyostelium discoideum complexed with MgADP.BeFx and MgADP.AlF4-. Biochemistry. 1995 Jul 18;34(28):8960–8972. doi: 10.1021/bi00028a004. [DOI] [PubMed] [Google Scholar]
  10. Geisterfer-Lowrance A. A., Christe M., Conner D. A., Ingwall J. S., Schoen F. J., Seidman C. E., Seidman J. G. A mouse model of familial hypertrophic cardiomyopathy. Science. 1996 May 3;272(5262):731–734. doi: 10.1126/science.272.5262.731. [DOI] [PubMed] [Google Scholar]
  11. Geisterfer-Lowrance A. A., Kass S., Tanigawa G., Vosberg H. P., McKenna W., Seidman C. E., Seidman J. G. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell. 1990 Sep 7;62(5):999–1006. doi: 10.1016/0092-8674(90)90274-i. [DOI] [PubMed] [Google Scholar]
  12. Harris D. E., Work S. S., Wright R. K., Alpert N. R., Warshaw D. M. Smooth, cardiac and skeletal muscle myosin force and motion generation assessed by cross-bridge mechanical interactions in vitro. J Muscle Res Cell Motil. 1994 Feb;15(1):11–19. doi: 10.1007/BF00123828. [DOI] [PubMed] [Google Scholar]
  13. Highashihara M., Frado L. L., Craig R., Ikebe M. Inhibition of conformational change in smooth muscle myosin by a monoclonal antibody against the 17-kDa light chain. J Biol Chem. 1989 Mar 25;264(9):5218–5225. [PubMed] [Google Scholar]
  14. Ikebe M., Hartshorne D. J. Proteolysis of smooth muscle myosin by Staphylococcus aureus protease: preparation of heavy meromyosin and subfragment 1 with intact 20 000-dalton light chains. Biochemistry. 1985 Apr 23;24(9):2380–2387. doi: 10.1021/bi00330a038. [DOI] [PubMed] [Google Scholar]
  15. Jaenicke T., Diederich K. W., Haas W., Schleich J., Lichter P., Pfordt M., Bach A., Vosberg H. P. The complete sequence of the human beta-myosin heavy chain gene and a comparative analysis of its product. Genomics. 1990 Oct;8(2):194–206. doi: 10.1016/0888-7543(90)90272-v. [DOI] [PubMed] [Google Scholar]
  16. Kelley C. A., Takahashi M., Yu J. H., Adelstein R. S. An insert of seven amino acids confers functional differences between smooth muscle myosins from the intestines and vasculature. J Biol Chem. 1993 Jun 15;268(17):12848–12854. [PubMed] [Google Scholar]
  17. Kurabayashi M., Komuro I., Tsuchimochi H., Takaku F., Yazaki Y. Molecular cloning and characterization of human atrial and ventricular myosin alkali light chain cDNA clones. J Biol Chem. 1988 Sep 25;263(27):13930–13936. [PubMed] [Google Scholar]
  18. Kurabayashi M., Tsuchimochi H., Komuro I., Takaku F., Yazaki Y. Molecular cloning and characterization of human cardiac alpha- and beta-form myosin heavy chain complementary DNA clones. Regulation of expression during development and pressure overload in human atrium. J Clin Invest. 1988 Aug;82(2):524–531. doi: 10.1172/JCI113627. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Liew C. C., Sole M. J., Yamauchi-Takihara K., Kellam B., Anderson D. H., Lin L. P., Liew J. C. Complete sequence and organization of the human cardiac beta-myosin heavy chain gene. Nucleic Acids Res. 1990 Jun 25;18(12):3647–3651. doi: 10.1093/nar/18.12.3647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Lutz R. A., Bull C., Rodbard D. Computer analysis of enzyme-substrate-inhibitor kinetic data with automatic model selection using IBM-PC compatible microcomputers. Enzyme. 1986;36(3):197–206. doi: 10.1159/000469292. [DOI] [PubMed] [Google Scholar]
  21. Margossian S. S. Reversible dissociation of dog cardiac myosin regulatory light chain 2 and its influence on ATP hydrolysis. J Biol Chem. 1985 Nov 5;260(25):13747–13754. [PubMed] [Google Scholar]
  22. Marian A. J., Roberts R. Recent advances in the molecular genetics of hypertrophic cardiomyopathy. Circulation. 1995 Sep 1;92(5):1336–1347. doi: 10.1161/01.cir.92.5.1336. [DOI] [PubMed] [Google Scholar]
  23. Maron B. J., Bonow R. O., Cannon R. O., 3rd, Leon M. B., Epstein S. E. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (2). N Engl J Med. 1987 Apr 2;316(14):844–852. doi: 10.1056/NEJM198704023161405. [DOI] [PubMed] [Google Scholar]
  24. McNally E. M., Kraft R., Bravo-Zehnder M., Taylor D. A., Leinwand L. A. Full-length rat alpha and beta cardiac myosin heavy chain sequences. Comparisons suggest a molecular basis for functional differences. J Mol Biol. 1989 Dec 5;210(3):665–671. doi: 10.1016/0022-2836(89)90141-1. [DOI] [PubMed] [Google Scholar]
  25. Onishi H., Morales M. F., Katoh K., Fujiwara K. The putative actin-binding role of hydrophobic residues Trp546 and Phe547 in chicken gizzard heavy meromyosin. Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):11965–11969. doi: 10.1073/pnas.92.26.11965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Persechini A., Kamm K. E., Stull J. T. Different phosphorylated forms of myosin in contracting tracheal smooth muscle. J Biol Chem. 1986 May 15;261(14):6293–6299. [PubMed] [Google Scholar]
  27. Rayment I., Holden H. M., Sellers J. R., Fananapazir L., Epstein N. D. Structural interpretation of the mutations in the beta-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy. Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3864–3868. doi: 10.1073/pnas.92.9.3864. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Rayment I., Holden H. M., Whittaker M., Yohn C. B., Lorenz M., Holmes K. C., Milligan R. A. Structure of the actin-myosin complex and its implications for muscle contraction. Science. 1993 Jul 2;261(5117):58–65. doi: 10.1126/science.8316858. [DOI] [PubMed] [Google Scholar]
  29. Rayment I., Rypniewski W. R., Schmidt-Bäse K., Smith R., Tomchick D. R., Benning M. M., Winkelmann D. A., Wesenberg G., Holden H. M. Three-dimensional structure of myosin subfragment-1: a molecular motor. Science. 1993 Jul 2;261(5117):50–58. doi: 10.1126/science.8316857. [DOI] [PubMed] [Google Scholar]
  30. Sata M., Matsuura M., Ikebe M. Characterization of the motor and enzymatic properties of smooth muscle long S1 and short HMM: role of the two-headed structure on the activity and regulation of the myosin motor. Biochemistry. 1996 Aug 27;35(34):11113–11118. doi: 10.1021/bi960435s. [DOI] [PubMed] [Google Scholar]
  31. Sata M., Sugiura S., Yamashita H., Momomura S., Serizawa T. Dynamic interaction between cardiac myosin isoforms modifies velocity of actomyosin sliding in vitro. Circ Res. 1993 Oct;73(4):696–704. doi: 10.1161/01.res.73.4.696. [DOI] [PubMed] [Google Scholar]
  32. Schwartz K., Carrier L., Guicheney P., Komajda M. Molecular basis of familial cardiomyopathies. Circulation. 1995 Jan 15;91(2):532–540. doi: 10.1161/01.cir.91.2.532. [DOI] [PubMed] [Google Scholar]
  33. Schwartz K., Lompre A. M., Bouveret P., Wisnewsky C., Whalen R. G. Comparisons of rat cardiac myosins at fetal stages in young animals and in hypothyroid adults. J Biol Chem. 1982 Dec 10;257(23):14412–14418. [PubMed] [Google Scholar]
  34. Smith C. A., Rayment I. X-ray structure of the magnesium(II).ADP.vanadate complex of the Dictyostelium discoideum myosin motor domain to 1.9 A resolution. Biochemistry. 1996 Apr 30;35(17):5404–5417. doi: 10.1021/bi952633+. [DOI] [PubMed] [Google Scholar]
  35. Spudich J. A., Watt S. The regulation of rabbit skeletal muscle contraction. I. Biochemical studies of the interaction of the tropomyosin-troponin complex with actin and the proteolytic fragments of myosin. J Biol Chem. 1971 Aug 10;246(15):4866–4871. [PubMed] [Google Scholar]
  36. Stein L. A., White M. P. Biochemical kinetics of porcine cardiac subfragment-1. Circ Res. 1987 Jan;60(1):39–49. doi: 10.1161/01.res.60.1.39. [DOI] [PubMed] [Google Scholar]
  37. Sweeney H. L., Straceski A. J., Leinwand L. A., Tikunov B. A., Faust L. Heterologous expression of a cardiomyopathic myosin that is defective in its actin interaction. J Biol Chem. 1994 Jan 21;269(3):1603–1605. [PubMed] [Google Scholar]
  38. Tsuchimochi H., Sugi M., Kuro-o M., Ueda S., Takaku F., Furuta S., Shirai T., Yazaki Y. Isozymic changes in myosin of human atrial myocardium induced by overload. Immunohistochemical study using monoclonal antibodies. J Clin Invest. 1984 Aug;74(2):662–665. doi: 10.1172/JCI111466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. VanBuren P., Harris D. E., Alpert N. R., Warshaw D. M. Cardiac V1 and V3 myosins differ in their hydrolytic and mechanical activities in vitro. Circ Res. 1995 Aug;77(2):439–444. doi: 10.1161/01.res.77.2.439. [DOI] [PubMed] [Google Scholar]
  40. Watkins H., Rosenzweig A., Hwang D. S., Levi T., McKenna W., Seidman C. E., Seidman J. G. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med. 1992 Apr 23;326(17):1108–1114. doi: 10.1056/NEJM199204233261703. [DOI] [PubMed] [Google Scholar]
  41. Weeds A. G., Taylor R. S. Separation of subfragment-1 isoenzymes from rabbit skeletal muscle myosin. Nature. 1975 Sep 4;257(5521):54–56. doi: 10.1038/257054a0. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES